Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 8, 2006, Pages 733-735

  Mathiesen, Sofie ^a   Stenz Justesen, Ulrik ^b   Von L̈ttichau, Hans Rudolf ^a   Eg Hansen, Ann Brit ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; LOPINAVIR;

ADULT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; FATIGUE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENETICS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CENTRAL NERVOUS SYSTEM DISEASES; DRUG MONITORING; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; OXAZINES; OXIDOREDUCTASES, N-DEMETHYLATING; PYRIMIDINONES;

EID: 33746644548     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500504109     Document Type: Article

References (11)

1. Ward, BA and Gorski, JC and Jones, DR and Hall, SD and Flockhart, DA and Desta, Z. (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J Pharmacol Exp Ther, 306, pp. 287-300.
2. Haas, DW and Ribaudo, HJ and Kim, RB and Tierney, C and Wilkinson, GR and Gulick, RM and (2004) Pharmacogenetics of efavirenz and central nervous system side-effects: An Adult AIDS Clinical Trials Group study AIDS, 18, pp. 2391-400.
3. Rotger, M and Colombo, S and Furrer, H and Bleiber, G and Buclin, T and Lee, BL and (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients Pharmacogenet Genomics, 15, pp. 1-5.
4. Tsuchiya, K and Gatanaga, H and Tachikawa, N and Teruya, K and Kikuchi, Y and Yoshino, M and (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens Biochem Biophys Res Commun, 319, pp. 1322-6.
5. Marzolini, C and Telenti, A and Decosterd, LA and Greub, G and Biollaz, J and Buclin, T. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side-effects in HIV-1-infected patients AIDS, 15, pp. 71-5.
6. Nunez, M and Gonzalez, dR and Gallego, L and Jimenez-Nacher, I and Gonzalez-Lahoz, J and Soriano, V. (2001) Higher efavirenz plasma levels correlate with development of insomnia J Acquir Immune Defic Syndr, 28, pp. 399-400.
7. Stahle, L and Moberg, L and Svensson, JO and Sonnerborg, A. (2004) Efavirenz plasma concentrations in HIV-infected patients: Inter- and intra-individual variability and clinical effects Ther Drug Monit, 26, pp. 267-70.
8. Rodriguez-Novoa, S and Barreiro, P and Rendon, A and Jimenez-Nacher, I and Gonzalez-Lahoz, J and Soriano, V. (2005) Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects Clin Infect Dis, 40, pp. 1358-61.
9. Hariparsad, N and Nallani, SC and Sane, RS and Buckley, DJ and Buckley, AR and Desai, PB. (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbitol J Clin Pharmacol, 44, pp. 1273-81.
10. Mouly, S and Lown, KS and Kornhauser, D and Joseph, JL and Fiske, WD and Benedek, IH and (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans Clin Pharmacol Ther, 72, pp. 1-9.
11. Justesen, US and Pedersen, C. (2002) Diurnal variation of plasma protease inhibitor concentrations AIDS, 16, pp. 2487-9.